21. The Committee agreed that in the interest of facilitating the advancement of MRLs, individual residue/tissue combinations for the same species should not normally advance at different steps within the Codex step procedure. The Committee felt that this would prevent possible distortions in trade due to the use of compounds which targeted multiple tissues.
Carazolol
22. The Committee advanced the draft MRLs for pigs (muscle, fat/skin, liver, kidney) to Step 8, with the understanding that the footnote referencing concentrations at the injection site would be removed from the MRLs for liver and kidney as it was irrelevant to these tissues. The Committee noted that in muscle and fat/skin the concentration of carazolol at the injection site may exceed the ADI. The delegation of Canada and observer of Consumers International opposed advancing the MRLs to step 8 because the ingestion of residues at the injection site could result in an acute pharmocological response, as noted by JECFA.
Ceftiofur
23. The Committee noted that provisional methods of analysis had been recommended for pigs (muscle, liver, kidney). The Committee retained the draft MRLs for muscle, liver, kidney, fat (cattle, pigs) and milk (cattle) at Step 7 pending the re-evaluation of the compound at the 48th JECFA meeting.
Diminazene
24. The Committee noted that a provisional method of analysis had been recommended for milk (cattle). The Committee advanced the draft MRLs for cattle (muscle, liver, kidney, milk) to Step 8.
Doramectin
25. The Committee noted that provisional methods of analysis had been recommended for cattle Giver, fat). The Committee advanced the draft MRLs for cattle (muscle, liver, kidney, fat) to Step 8, with the understanding that the footnote concerning the high concentration of residues at the injection site would be removed from the MRLs for liver and kidney as it was irrelevant to these tissues.
Levamisole
26. The Committee noted that routine methods of analysis were available as part of national monitoring programmes. The Committee therefore advanced the draft MRLs for liver (poultry), muscle, kidney and fat (cattle, pigs, sheep, poultry) to Step 8.
Moxidectin
27. The Committee noted that methods of analysis had been recommended for cattle and sheep (muscle, liver, kidney, fat). The Committee advanced the MRL of 20 µg/kg for cattle muscle to step 8. It noted proposals to increase the MRL to 50 µg/kg and requested that JECFA re-evaluate this MRL at its 48th meeting to determine if it could be raised to 50 µg/kg. The Committee requested JECFA to advise the Commission of its opinion on raising the MRL from 20 µg/kg to 50 µg/kg and indicated that it would support such an increase on the basis of JECFA's opinion.
28. The Committee advanced the remaining draft MRLs for muscle (sheep), liver, kidney and fat (cattle, sheep) to Step 8.
29. The Committee noted that multiple doses of the compound might lead to residues above the MRL in fat tissues and agreed that this matter be considered by the 48th JECFA.
Spiramycin
30. The Committee advanced the draft MRLs for muscle, liver, kidney and fat (cattle, pigs, chickens) to Step 8. The Committee advanced the MRL of 100 µg/kg for cattle milk to step 8. It noted proposals to increase the MRL to 200 µg/kg and requested that JECFA re-evaluate this MRL at its 48th meeting to determine if it could be raised to 200 µg/kg. The Committee requested JECFA to advise the Commission of its opinion on raising the MRL from 100 µg/kg to 200 µg/kg and indicated that it would support such an increase on the basis of JECFA's opinion.
Triclabendazole
31. The Committee advanced the draft MRLs for fat (cattle, sheep) to Step 8. STATUS OF DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS
32. Draft maximum residue limits for veterinary drugs are contained in Appendix II (advanced to Step 8) and Appendix III (retained at Step 7) to this report.
